Australia Pharmaceuticals and Healthcare Report Q3 2013

Business Monitor International Market Research Reports Market Reports Online XML Feed

Australia Pharmaceuticals and Healthcare Report Q3 2013 May 8th 2013, 00:00 BMI View: As a developed market, Australia represents opportunities for risk averse pharmaceuticalinvestors, given its ageing and generally affluent population. Importantly, the government is implementingcost-cutting measures to cope with escalating healthcare costs, therefore generic drugmakers will stand tobenefit from the patented to generic drug switch. However, given that generic costs is higher in Australia ascompared to other developed countries, a downside risk to the view is the lack of generic substitution, givenno apparent benefits to patients.Headline Expenditure Projections? Pharmaceuticals: AUD13.47bn (US$13.95bn) in 2012 to AUD13.95bn (US$13.94bn) ...

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions